FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
Pharmasset Inc [ VRUS ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 02/04/2008 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 02/04/2008 | J(1) | 1,500,000(2) | D | $0 | 2,651,132(3) | I | See Footnote(4) | ||
Common Stock | 02/04/2008 | S | 27,300(5) | D | $23.86 | 2,623,832 | I | See Footnote(6) | ||
Common Stock | 02/04/2008 | J(1) | 57,353 | A | $0 | 57,353 | I | See Footnote(7) | ||
Common Stock | 02/04/2008 | J(1) | 27,925 | A | $0 | 27,925 | I | See Footnote(8) | ||
Common Stock | 02/04/2008 | J(1) | 35,558 | A | $0 | 35,558 | I | See Footnote(9) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
Explanation of Responses: |
1. Pro rata distribution of partnership interests. |
2. These shares were distributed as follows: 685,501 shares by BB BioVentures, L.P. ("BBBV"), 92,412 shares by MPM BioVentures Parallel Fund, L.P. ("BV PF"), 8,175 shares by MPM Asset Management Investors 1999 LLC ("AM 1999"), 39,814 shares by MPM BioVentures III, L.P., ("BV III"), 592,101 shares by MPM BioVentures III-QP, L.P. ("BV III QP"), 50,038 shares held by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BV KG"), 17,883 shares by MPM BioVentures III Parallel Fund, L.P. ("BV III PF") and 14,076 shares held by MPM Asset Management Investors 2004 BVIII LLC ("AM BV III"). MPM BioVentures I, L.P. ("BV I") and MPM BioVentures I LLC ("BV I LLC") are the direct and indirect general partners of BV PF. BAB BioVentures L.P. ("BAB BV"), BAB BioVentures, N.V. ("BAB NV") and BV I LLC are the direct and indirect general partners of BBBV. Luke Evnin, Michael Steinmetz and Ansbert Gadicke are the managers of AM 1999 and BV I LLC. MPM BioVentures III GP, L.P. ("BV III GP") and MPM BioVentures III LLC ("BV III LLC") are the direct and indirect general partners of BV III, BV III QP, BV III PF and BV KG. Luke Evnin, Michael Steinmetz and Ansbert Gadicke are members of BV III LLC and AM BV III. Each Reporting Person disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein. |
3. On October 18, 2007, additional shares were received pursuant to a declaration of a stock dividend as follows: 7,745 by BBBV, 879 by BV PF, 90 by AM 1999, 2,672 by BV III, 39,748 by BV III QP, 3,359 by BV KG, 1,200 by BV III PF and 944 by AM BV III. |
4. The shares are held as follows: 1,211,570 by BBBV, 163,332 by BV PF, 14,448 by AM 1999, 70,369 by BV III, 1,046,493 by BV III QP, 88,437 by BV KG, 31,606 by BV III PF and 24,877 by AM BV III. Each Reporting Person disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein. |
5. The shares were sold as follows: 12,476 by BBBV, 1,682 by BV PF, 149 by AM 1999, 725 by BV III, 10,776 by BV III QP, 911 by BV KG, 325 by BV III PF and 256 by AM BV III. |
6. The shares are held as follows: 1,199,094 by BBBV, 161,650 by BV PF, 14,299 by AM 1999, 69,644 by BV III, 1,035,717 by BV III QP, 87,526 by BV KG, 31,281 by BV III PF and 24,621 by AM BV III. Each Reporting Person disclaims beneficial ownership of all such shares except to the extent of their respective proportionate pecuniary interests therein. |
7. The shares are held by Luke Evnin. |
8. The shares are held by Michael Steinmetz. |
9. The shares are held as follows: 29,369 by Ansbert Gadicke and 6,189 by The Gadicke Irrevocable Trust, of which Mr. Gadicke is a trustee. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein. |
By Ansbert Gadicke, managing director of BAB BioVentures NV, the general partner of BAB BioVentures L.P., the general partner of BB BioVentures L.P. /s/ Ansbert Gadicke | 02/06/2008 | |
By Ansbert Gadicke, managing director of BAB BioVentures NV, the general partner of BAB BioVentures L.P. /s/ Ansbert Gadicke | 02/06/2008 | |
By Ansbert Gadicke, managing director of BAB BioVentures NV /s/ Ansbert Gadicke | 02/06/2008 | |
By Luke Evnin, manager of MPM Asset Management Investors 1999 LLC /s/ Luke Evnin | 02/06/2008 | |
By Luke Evnin, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P., the general partner of MPM BioVentures Parallel Fund, L.P. /s/ Luke Evnin | 02/06/2008 | |
By Luke Evnin, manager of MPM BioVentures I LLC, the general partner of MPM BioVentures I L.P. /s/ Luke Evnin | 02/06/2008 | |
By Luke Evnin, manager of MPM BioVentures I LLC /s/ Luke Evnin | 02/06/2008 | |
/s/ Luke Evnin | 02/06/2008 | |
/s/ Michael Steinmetz | 02/06/2008 | |
/s/ Ansbert Gadicke | 02/06/2008 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |